Innovative nanoparticle research could restore antibiotic efficacy
Disrupting drug-resistant Gram-negative pathogens is a potential breakthrough in addressing AMR and enhancing antibiotic success.
List view / Grid view
Disrupting drug-resistant Gram-negative pathogens is a potential breakthrough in addressing AMR and enhancing antibiotic success.
General Manager Brian Morrissey discuss his company’s acquisition of fellow Beta-Lactam manufacturer Athlone Laboratories and its implications for an evolving industry.
The move consolidates Ireland’s two leading producers of the antibiotics.
CDMOs weigh up how to meet manufacturing demands across oral solid doses, monoclonal antibodies, ADCs and beyond.
Supply crisis of antibiotics in Europe adds burden to regional efforts to overcome antimicrobial resistance (AMR), says a new report.
As an important policy tool, the new editions by the WHO mark a “significant” step in broadening access to new medicines with proven clinical benefits.
Based on the clinical trial results, the drugs could particularly benefit tuberculosis patients requiring extended therapeutic intervention.
MHRA’s publication is intended to support European developers of phage-based medicinal products to effectively navigate related regulations.
The EMA’s committee has granted positive opinions for ten new treatments, including medicines for oncology indications and rare diseases.
IMA Pharma discusses approaches to keeping Amoxicillin and Clavulanic Acid tablets stable and effective by addressing moisture sensitivity and preventing degradation.
The World Health Organization (WHO) asserts that vaccines could reduce antibiotic use as well as economic costs of antimicrobial resistance (AMR) worldwide.
The recommendations offered in the guidance is applicable across different areas of manufacturing, from active pharmaceutical ingredients (APIs), through to formulation and packaging.
The new manufacturing facility for antibody drug conjugates (ADCs) will be designed to have zero carbon emissions when operational, AstraZeneca stated.
The CEO of GSK shared that the company is “proud to be a founding partner, and hope others will join us to support this urgent priority” in tackling AMR.
Safety of the compounded biologic was confirmed following 28-day storage in two different polypropylene syringe types, research shows.